Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring.

IF 4.5 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Inflammatory Bowel Diseases Pub Date : 2025-05-09 DOI:10.1093/ibd/izaf052

Ralley E Prentice, Steven X Cho, Sally J Bell, Claudia A Nold-Petry, Marie Lee, Indiana Zorkau, Megan Burns, Emily K Wright, Emma Flanagan, Marcel F Nold, Rimma Goldberg

{"title":"Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring.","authors":"Ralley E Prentice, Steven X Cho, Sally J Bell, Claudia A Nold-Petry, Marie Lee, Indiana Zorkau, Megan Burns, Emily K Wright, Emma Flanagan, Marcel F Nold, Rimma Goldberg","doi":"10.1093/ibd/izaf052","DOIUrl":null,"url":null,"abstract":"Background and aims: Inflammatory bowel disease (IBD) therapeutics and pregnancy itself are known to impact immune cell populations, but a detailed understanding of the effect of specific therapies is lacking, particularly for infants exposed in utero. With comprehensive flow cytometric assessment, we aimed to explore how IBD and its treatment impact both maternal and infant immunophenotypes and cytokine production.Methods: Peripheral blood was taken for flow cytometry immunophenotyping and quantification of cytokine responses to stimulation from women with IBD and healthy controls throughout pregnancy, at delivery, and postpartum. Blood samples were also taken from the umbilical cord and peripherally from the resultant offspring at the age of 6 weeks.Results: Eighteen participants (16 with IBD and 2 healthy controls) were recruited to this single-center prospective cohort study. Basal T regulatory cell population proportions were 46% lower (0.21% vs 0.39%, P = .027) in those participants exposed to ustekinumab (n = 4). No other significant differences were noted in immunophenotype according to drug therapy exposure. Basal (1.75% vs 0.47%, P = .036) and lipopolysaccharide-stimulated (72.2% vs 64.7%, P = .028) production of tumour necrosis factor by classical dendritic cells were increased 3.7- and 1.1-fold, respectively, in those with an elevated fecal calprotectin (n = 6). Basal CD4+α4β7+ (41.4% to 66.5%, P = .0043) and CD8+α4β7+ (81.2% to 93.6%, P = .007) population proportions increased 1.6- and 1.2-fold, respectively, in infants from birth to 6 weeks.Conclusions: This study provides the foundation for ongoing investigation to more definitively extricate the impact of maternal IBD activity, drug exposures, and disease phenotype on infant immune system development and function. These novel data suggest that IBD pharmacotherapies may not significantly impact maternal or infant immune regulation.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Bowel Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ibd/izaf052","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims: Inflammatory bowel disease (IBD) therapeutics and pregnancy itself are known to impact immune cell populations, but a detailed understanding of the effect of specific therapies is lacking, particularly for infants exposed in utero. With comprehensive flow cytometric assessment, we aimed to explore how IBD and its treatment impact both maternal and infant immunophenotypes and cytokine production.

Methods: Peripheral blood was taken for flow cytometry immunophenotyping and quantification of cytokine responses to stimulation from women with IBD and healthy controls throughout pregnancy, at delivery, and postpartum. Blood samples were also taken from the umbilical cord and peripherally from the resultant offspring at the age of 6 weeks.

Results: Eighteen participants (16 with IBD and 2 healthy controls) were recruited to this single-center prospective cohort study. Basal T regulatory cell population proportions were 46% lower (0.21% vs 0.39%, P = .027) in those participants exposed to ustekinumab (n = 4). No other significant differences were noted in immunophenotype according to drug therapy exposure. Basal (1.75% vs 0.47%, P = .036) and lipopolysaccharide-stimulated (72.2% vs 64.7%, P = .028) production of tumour necrosis factor by classical dendritic cells were increased 3.7- and 1.1-fold, respectively, in those with an elevated fecal calprotectin (n = 6). Basal CD4+α4β7+ (41.4% to 66.5%, P = .0043) and CD8+α4β7+ (81.2% to 93.6%, P = .007) population proportions increased 1.6- and 1.2-fold, respectively, in infants from birth to 6 weeks.

Conclusions: This study provides the foundation for ongoing investigation to more definitively extricate the impact of maternal IBD activity, drug exposures, and disease phenotype on infant immune system development and function. These novel data suggest that IBD pharmacotherapies may not significantly impact maternal or infant immune regulation.

查看原文本刊更多论文

孕妇及其后代的先天性和适应性免疫不受炎症性肠病药物的影响。

背景和目的：已知炎症性肠病（IBD）治疗和妊娠本身会影响免疫细胞群，但缺乏对特定治疗效果的详细了解，特别是对子宫内暴露的婴儿。通过全面的流式细胞术评估，我们旨在探索IBD及其治疗如何影响母婴免疫表型和细胞因子的产生。方法：采用流式细胞术对IBD患者和健康对照者的外周血进行免疫分型和细胞因子定量分析，观察她们在妊娠、分娩和产后对刺激的反应。在6周龄时，还从所生后代的脐带和外周血中采集了血液样本。结果：18名参与者（16名IBD患者和2名健康对照）被招募到这项单中心前瞻性队列研究中。在暴露于ustekinumab （n = 4）的参与者中，基础T调节细胞群比例降低了46% （0.21% vs 0.39%, P = 0.027）。根据药物治疗暴露，免疫表型没有其他显着差异。在粪钙保护蛋白升高（n = 6）的人群中，经典树突状细胞产生的肿瘤坏死因子的基础（1.75% vs 0.47%, P = 0.036）和脂多糖刺激（72.2% vs 64.7%, P = 0.028）分别增加了3.7倍和1.1倍。从出生到6周，CD4+α4β7+ (41.4% ~ 66.5%, P = 0.0043)和CD8+α4β7+ (81.2% ~ 93.6%, P = 0.007)人群比例分别增加1.6倍和1.2倍。结论：本研究为进一步研究更明确地了解母体IBD活性、药物暴露和疾病表型对婴儿免疫系统发育和功能的影响提供了基础。这些新数据表明，IBD药物治疗可能不会显著影响母亲或婴儿的免疫调节。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammatory Bowel Diseases 医学-胃肠肝病学

CiteScore

9.70

自引率

6.10%

发文量

462

审稿时长

1 months

期刊介绍： Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.